GlobalRPh RX List - NIMBEX
- Product / population
- NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.
- Renal measure
- ESRD and renal PK/PD; no new renal-dose calculation
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Separate onset and metabolite accumulation from recovery duration.
Selected named sections only; not a complete monograph or independent clinical approval.
A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.
Renal dosing, restrictions and evidence limits
In the selected ESRD study, recovery after a 0.1 mg/kg study dose was not clinically altered, but onset of blockade was slower. The mirror advises considering at least one additional minute between administration and attempted intubation, with peripheral nerve-stimulator assessment of adequacy and subsequent dosing.
Predominantly organ-independent parent-drug elimination does not eliminate all renal considerations: metabolite half-lives are longer in ESRD and concentrations may rise during prolonged administration. This study dose is not a universal recommended intubating dose, and the selected evidence does not establish a dialysis supplement.